Chromosome Maintenance Group, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK.
Chromosome Maintenance Group, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK
Open Biol. 2017 Mar;7(3). doi: 10.1098/rsob.160338.
Aberrant activation of telomerase occurs in 85-90% of all cancers and underpins the ability of cancer cells to bypass their proliferative limit, rendering them immortal. The activity of telomerase is tightly controlled at multiple levels, from transcriptional regulation of the telomerase components to holoenzyme biogenesis and recruitment to the telomere, and finally activation and processivity. However, studies using cancer cell lines and other model systems have begun to reveal features of telomeres and telomerase that are unique to cancer. This review summarizes our current knowledge on the mechanisms of telomerase recruitment and activation using insights from studies in mammals and budding and fission yeasts. Finally, we discuss the differences in telomere homeostasis between normal cells and cancer cells, which may provide a foundation for telomere/telomerase targeted cancer treatments.
端粒酶的异常激活发生在所有癌症的 85-90%中,这为癌细胞绕过增殖限制提供了能力,使它们成为不死的。端粒酶的活性在多个水平上受到严格控制,从端粒酶成分的转录调控到全酶的生物发生和招募到端粒,最后是激活和持续性。然而,使用癌细胞系和其他模型系统的研究已经开始揭示出端粒和端粒酶在癌症中的独特特征。这篇综述总结了我们使用哺乳动物和芽殖酵母和裂殖酵母研究中的见解,对端粒酶募集和激活机制的现有认识。最后,我们讨论了正常细胞和癌细胞中端粒动态平衡的差异,这可能为端粒/端粒酶靶向癌症治疗提供基础。